Noile-Immune BiotechTSE:4893 53 Market Cap is 円5,326.10 Mil as of Jul. 03, 2026. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,426 Biotechnology companies, Noile-Immune Biotech ranks worse than 69.64% on this metric.
Noile-Immune Biotech's quarterly market cap
increased
from Mar. 2025 (円6,971.62 Mil) to Jun. 2025 (円7,404.64 Mil) but then
declined
from Jun. 2025 (円7,404.64 Mil) to Dec. 2025 (円5,759.17 Mil).
Noile-Immune Biotech's annual market cap
declined
from Dec. 2023 (円9,174.72 Mil) to Dec. 2024 (円7,361.34 Mil) and
declined
from Dec. 2024 (円7,361.34 Mil) to Dec. 2025 (円5,759.17 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Noile-Immune Biotech's Enterprise Value for Today is 円1,582.56 Mil.
Noile-Immune Biotech (TSE:4893) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Noile-Immune Biotech Market Cap Related Terms
Noile-Immune Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Noile-Immune Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech (TSE:4893) has a Market Cap of 円5,326.10 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Noile-Immune Biotech and its competitors. According to the industry distribution chart, Noile-Immune Biotech ranks #993 out of 1426 companies in the Biotechnology industry, placing it in the top 69.6%.
Is Noile-Immune Biotech's Market Cap too high?
Noile-Immune Biotech's current Market Cap is 円5,326.10 Mil. Based on the distribution chart, Noile-Immune Biotech ranks #993 out of 1426 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #993 out of 1426 companies for Market Cap. This places Noile-Immune Biotech in the lower half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Market Cap is 円5,326.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円123.00 — trading 2721.1% above its estimated fair value. The current Market Cap is 円5,326.10 Mil. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Market Cap is 円5,326.10 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円123.00 is trading 2721.1% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Market Cap: 円5,326.10 Mil
GF Value™: 円4.36 vs. price of 円123.00 (2721.1% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
